Kiniksa Pharmaceuticals, Ltd. provided earnings guidance for the full-year 2022. For the year, the company expects ARCALYST net revenue for the full-year 2022 to be between $115 million and $130 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.52 USD | +2.68% | +1.94% | +10.66% |
14/05 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
23/04 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.66% | 1.35B | |
+13.15% | 118B | |
+12.77% | 106B | |
-3.97% | 24.28B | |
+1.16% | 21.96B | |
-9.30% | 18.16B | |
-42.12% | 16.37B | |
-17.23% | 15.56B | |
+4.78% | 13.63B | |
+32.27% | 12.27B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Earnings Guidance for the Full-Year 2022